@article{ATM23763,
author = {Philip Friedlander},
title = {The use of baseline tumor size to prognosticate overall survival in stage IV melanoma patients treated with the PD-1 inhibitor pembrolizumab},
journal = {Annals of Translational Medicine},
volume = {7},
number = {Suppl 1},
year = {2019},
keywords = {},
abstract = {Historically patients who developed stage IV melanoma were expected to live less than one year. Clinical outcome was heterogeneous as evidenced by a tail end to the overall survival (OS) curve which identifies a small subset of patients, encompassing less than 10% of the total population, who are long term survivors (1).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/23763}
}